Top Feature

Dec 15, 2014
Pharmaceutical Executive
Foreign governments are enacting anti-fraud legislation as part of broader efforts to crack down on corrupt practices involving pharmaceutical companies and healthcare professionals.
Dec 14, 2014
Pharmaceutical Executive
Two words define the future of commercialization project management: Faster and Better
Dec 12, 2014
Pharmaceutical Executive
The science of drug discovery is back on script—and the stars are cued up for a new generation of breakthrough therapies. But is pharma ready to raise its game and cut a deal with all those "prove it to me" payers?
Dec 11, 2014
Pharmaceutical Executive
AmerisourceBergen exemplifies the shift underway among pharma's supply chain drivers, best summarized as "follow the customer". Company veteran Peyton Howell tells us more.
Dec 10, 2014
Pharmaceutical Executive
Rebecca Ashkenazy, Alex Chang, Cyndi Green, Ted Miller, and Christine de los Reyes discuss how the 3S framework - science, synergy, and survival -- can build more value in biopharmaceutical dealmaking.
Dec 03, 2014
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Michael Scholl, Karl-Hubertus Gruber and Michael Marquardt look to the future of the immunodiagnostics market and see more consolidation ahead.
Nov 11, 2014
By Pharmaceutical Executive Editors
Merck KGaA CEO Stefan Oschmann spoke last week in New York as he accepted the two-year role as president of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).
Sep 28, 2014
By Pharmaceutical Executive Editors
Although progress has been made in bringing biosimilars to market, gaps in requirements for testing and documenting product similarity are still hampering the EU, U.S., and other regions, writes Jill Wechsler.
Sep 22, 2014
By Pharmaceutical Executive Editors
The EU may have a new monitoring scheme for Iceland's volatile geology, but it should also heed the volcano that could blow apart its assumptions on drug pricing and reimbursement, says Reflector.
Jul 31, 2014
By Pharmaceutical Executive Editors
The Galien Foundation and the French government investment agency UBIFRANCE have partnered to establish UBISTART, a transatlantic payout for the best in start-up innovations. William Looney reports.
native1_300x100
lorem ipsum